Last reviewed · How we verify
Fampyra — Competitive Intelligence Brief
phase 2
Voltage-gated potassium channel, Potassium voltage-gated channel subfamily C member 1, Potassium voltage-gated channel subfamily C member 2
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
Fampyra (Fampyra) — Vestre Viken Hospital Trust.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fampyra TARGET | Fampyra | Vestre Viken Hospital Trust | phase 2 | Voltage-gated potassium channel, Potassium voltage-gated channel subfamily C member 1, Potassium voltage-gated channel subfamily C member 2 | ||
| fampridine | fampridine | Biogen | marketed | Voltage-gated potassium channel, Potassium voltage-gated channel subfamily C member 1, Potassium voltage-gated channel subfamily C member 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Fampyra — Competitive Intelligence Brief. https://druglandscape.com/ci/fampyra. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing